Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Arts and Culture
- Broadcasting
- Constitutional Issues
- Consumer Issues
- Defence
- Education
- Employment and Training
- Energy
- Environment
- Financial Institutions
- Fisheries
- Forestry
- Government Procurement
- Health
- Immigration
- Industry
- Infrastructure
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Labour
- Mining
- Regional Development
- Research and Development
- Science and Technology
- Small Business
- Sports
- Taxation and Finance
- Telecommunications
- Tourism
- Transportation
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
- Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
- Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
Policies or Program
- Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
- The government's Science and Technology strategy as it relates to the biopharmaceutical industry
Regulation
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Competition Tribunal (CT)
-
Employment and Social Development Canada (ESDC)
-
Environment and Climate Change Canada (ECCC)
-
Finance Canada (FIN)
-
Fisheries and Oceans Canada (DFO)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
National Research Council (NRC)
-
Natural Resources Canada (NRCan)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Senate of Canada
-
Statistics Canada (StatCan)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
55 Metcalfe Street, Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Client representative
Pamela Fralick, President
Parent Company Information
Innovative Medicines Canada / Médicaments novateurs Canada is not a subsidiary of any other parent companies.
Coalition Members Information
Innovative Medicines Canada / Médicaments novateurs Canada is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Innovative Medicines Canada / Médicaments novateurs Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Innovative Medicines Canada / Médicaments novateurs Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
Stephane Berimbere
|
No public offices held
Business address:
50 O'Connor Street
Ottawa, ON K1P 6L2
Canada
Telephone number:
613-238-4371
Consultant Firm and Address
Firm:
Hill + Knowlton Strategies
Address:
50 O'Connor Street
Ottawa, ON K1P 6L2
Canada
Telephone number:
613-238-4371